希瑪眼科(03309.HK)擬先舊後新配售6800萬股 淨籌約3.876億港元
格隆匯 6 月 19日丨希瑪眼科(03309.HK)發佈公告,2020年6月19日,公司與希瑪集團有限公司作為賣方及配售代理香港上海匯豐銀行有限公司就配售事項及認購事項訂立該協議。根據該協議,配售代理按盡力基準以配售價每股5.80港元配售總共6800萬股現有股份,而賣方有條件同意按配售價認購數目與配售代理所配售配售股份數目相同的新股份。
擬配售股份相當於公司於該公告日期的已發行股本約6.32%及經認購事項擴大後的已發行股本約5.95%。配售價每股5.80港元較6月18日收市價6.56港元折讓約11.6%。預期配售事項將於2020年6月23日完成。
經扣除相關費用及開支後,估計公司將自認購事項收取的所得款項淨額約為3.876億港元。公司擬將認購事項所得款項淨額用於可能收購及╱或在中國設立眼科醫院及╱或用作集團的營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.